| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514210500 | 12 to 15 amino acid residues in the peptide chain | 43 |
| 20100286072 | RETRO-INVERSO PEPTIDES DERIVED FROM INTERLEUKIN-6 - This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage. | 11-11-2010 |
| 20100305051 | NATRIURETIC ACTIVITIES - This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided. | 12-02-2010 |
| 20110118195 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. | 05-19-2011 |
| 20110124583 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. | 05-26-2011 |
| 20110130348 | KINETICALLY EFFICIENT SUBSTRATE FOR LIPOIC ACID LIGASE - The invention provides methods for identifying and optimizing peptide substrates for enzymes such as lipoic acid ligase (Lp1A). | 06-02-2011 |
| 20110166082 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY - A method and compound for treating skeletal muscle mass deficiency in a human subject are disclosed. The composition is an oligomer of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, contains between 10-40 nucleotide bases, has a base sequence effective to hybridize to an expression-sensitive region of processed or preprocessed human myostatin RNA transcript, identified, in its processed form, by SEQ ID NO:6, and is capable of uptake by target muscle cells in the subject. In practicing the method, the compound is administered in an amount and at a dosage schedule to produce an overall reduction in the level of serum myostatin measured in the patient, and preferably to bring the myostatin level within the a range determined for normal, healthy individuals. | 07-07-2011 |
| 20110230427 | MATERIALS AND METHODS FOR STABILIZING NANOPARTICLES IN SALT SOLUTIONS - Sequence-specific polymers are proving to be a powerful approach to assembly and manipulation of matter on the nanometer scale. This has been most impressive in the case of DNA, and progress has been made toward templating inorganic nanoparticles using DNA nanostructures. One obstacle to this progress is that inorganic nanomaterials are often incompatible with DNA assembly conditions, which involve aqueous solutions high in either or both monovalent and divalent salt. Synthetic oligopeptide ligands have been shown by others to improve nanoparticle stability in high concentrations of monovalent salt. Ligands that are peptoids, or sequence-specific N-functional glycine oligomers, allow precise and flexible control over the arrangement of binding groups, steric spacers, charge, and other functionality. We have synthesized short peptoids that can prevent the aggregation of gold nanoparticles in high-salt environments including divalent salt, and allow co-adsorption of a single DNA molecule. This degree of precision and versatility is likely to prove essential in bottom-up assembly of nanostructures and in biomedical applications of nanomaterials. | 09-22-2011 |
| 20110275575 | PEPTIDE INHIBITORS OF PROTEIN KINASE C - PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described. | 11-10-2011 |
| 20120028912 | Methods of modulating bromodomains - The present invention features compounds useful for and methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods for treating HIV infection and HIV related disease. | 02-02-2012 |
| 20120028913 | PEPTIDES FOR INHIBITING CHEMOKINE BINDING TO CHEMOKINE RECEPTORS - Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides. | 02-02-2012 |
| 20120190630 | AMINO ACID-BASED COMPOUNDS, THEIR METHODS OF USE, AND METHODS OF SCREENING - Described herein are compounds that comprise amino acids and their pharmaceutical compositions. Methods used to administer the compounds are described. Screening methods including those for determining | 07-26-2012 |
| 20120202754 | ENHANCED SUBSTRATES FOR THE PROTEASE ACTIVITY OF SEROTYPE A BOTULINUM NEUROTOXIN - Substrates of botulinum toxin serotype A (BoNT A), kits comprising the substrates, and methods of using the substrates are disclosed. BoNT A cleaves SNAP-25 and the substrates that are based upon a portion of SNAP-25. Various amino acid modifications to the sequence of the peptide based on SNAP-25 are performed. Fluorescence labels that act as donors and acceptors may be added to the substrate to aid in the study of BoNT A. | 08-09-2012 |
| 20120208774 | METHOD FOR INHIBITING "MELANOMA INHIBITORY ACTIVITY" MIA - The present invention is directed to peptides, antibodies and antibody fragments inhibiting activity of “Melanoma Inhibitory Activity” (MIA). | 08-16-2012 |
| 20120245105 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR CONTRIBUTING TO THE TREATMENT OF SOLID TUMORS - Methods, compositions and articles of manufacture for contributing to the treatment of a solid cancerous tumor are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET | 09-27-2012 |
| 20120277166 | CONOTOXIN PEPTIDES USEFUL AS INHIBITORS OF NEURONAL AMINE TRANSPORTERS - The invention relates to an isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them. | 11-01-2012 |
| 20120309695 | CRYSTALLINE FORM OF LINACLOTIDE - The present invention relates to crystalline forms of linaclotide, as well as to various methods and processes for the preparation and use of the crystalline forms. | 12-06-2012 |
| 20130045928 | Uses of Natriuretic Peptide Constructs - Use of constructs which bind to one or more natriuretic peptide receptors and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: | 02-21-2013 |
| 20130072447 | ENHANCED ORAL TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGANOSTIC AGENTS - The invention is directed to pharmaceutical compositions and methods for delivery of a therapeutic or diagnostic agent from one bodily compartment to one or more other bodily compartment by administering one of the following conjugates: a polymer having multiple functional groups at least one of which is covalently bound to a therapeutic or diagnostic agent, and at least one cell uptake promoter covalently bound to the therapeutic or diagnostic agent; or a polymer and at least one cell uptake promoter bound thereto; the polymer further comprising multiple functional groups at least one of which is covalently bound a therapeutic or diagnostic agent. | 03-21-2013 |
| 20130130996 | PEPTIDES FOR INHIBITING CHEMOKINE BINDING TO CHEMOKINE RECEPTORS - Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides. | 05-23-2013 |
| 20130210749 | PEPTIDES, CONSTRUCTS AND USES THEREFOR - The invention provides novel peptides and constructs. In addition the invention provides methods for carrying compounds across the cell membrane, for antagonizing or destroying X-protein of HBV, treatment and/or management of HBV infection, treatment and/or prevention of HCC, and degradation of a target protein. | 08-15-2013 |
| 20130210750 | Polypeptide TF1 for Inhibiting Type 2 Shiga Toxin Activity, Encoding Gene for Same and Use Thereof - The present invention provides a polypeptide TF1 for inhibiting type-2 Shiga-toxin activity, an encoding gene for the same and use thereof. The present polypeptide is named TF1 (also known as P1); its amino acid sequence is shown in Sequence 1 in the sequence list. The polypeptide P1 can be prepared into medicine for preventing and/or treating diseases caused by type-2 Shiga toxin or the pathogens which produce type-2 Shiga toxin. | 08-15-2013 |
| 20130274207 | Uses of Natriuretic Peptide Constructs - Use of constructs which bind to one or more natriuretic peptide receptors and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: | 10-17-2013 |
| 20130316963 | INNATE DEFENCE REGULATORY PEPTIDE COMPOSITIONS FOR TREATMENT OF ARTHRITIS - A composition for preventing or treating inflammatory arthritis wherein the composition comprises an innate defence regulatory peptide named IDR-1002, said peptide comprising an amino acid sequence listing of VQRWLIVWRIRK, and/or a derivative thereof and/or an analog thereof. Use of the IDR-1002 peptide and/or a derivative thereof and/or an analog or a composition comprising the peptide and/or a derivative and/or analog to modulate the expression and/or function of an inflammatory cytokine and/or a matrix metallopeptidase-3 and/or a cell-signalling pathway. | 11-28-2013 |
| 20140005128 | TREATMENTS OF GASTROINTESTINAL DISORDERS | 01-02-2014 |
| 20140113875 | NOVEL SELF-ASSEMBLING DRUG AMPHIPHILES AND METHODS FOR SYNTHESIS AND USE - The present invention provides herein the design of monodisperse, amphiphilic anticancer drugs—which are now termed “drug amphiphiles” (DAs)—that can spontaneously associate into discrete, stable supramolecular nanostructures with the potential for self-delivery (no additional carriers are needed). The quantitative drug loading in the resulting nanostructures is ensured by the very nature of the molecular design. The DA is a composition comprising: D-L-PEP; wherein D is 1 to 4 hydrophobic drug molecules which can be the same or different; L is 1 to 4 biodegradable linkers which can be the same or different; and PEP is a peptide that can spontaneously associate into discrete, stable supramolecular nanostructures. In an alternate embodiment, the DA composition also comprises a targeting ligand (T). Methods of making DA molecules, as well as their use in treatment of disease are also provided. | 04-24-2014 |
| 20140206629 | Stromal Derived Factor Inhibition And CXCR4 Blockade - The invention relates to inhibition of SDF-1α expression in subacromial bursa cells by CXCR-4 inhibitors. Bursal cell migration in response to SDF-α stimulation is also decreased in the presence of CXCR4 inhibitors. Accordingly, provided are methods for treating or ameliorating a musculoskeletal disorder. | 07-24-2014 |
| 20140357578 | NOVEL THERAPEUTIC APPROACH FOR POLYGLUTAMINE DEGENERATION - Compositions, methods, and kits are provided for reduction of (CAG) | 12-04-2014 |
| 20150011483 | Inhibition of HIV-1 Infection by Potent Metallocene Conjugated Peptide Through Conformational Entrapment of Envelope GP120 - The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. | 01-08-2015 |
| 20150111836 | CELLULAR APOBEC3 PROTEINS AND MODULATORS THEREOF FOR REGULATING DNA REPAIR PROCESSES AND TREATING PROLIFERATIVE DISEASES - The present invention provides methods, compositions and kits for modulating DSB repair processes in a subject in need thereof. More specifically, the invention provides the use of compounds that modulate the expression or activity of at least one APOBEC family member for modulating DSB repair processes. | 04-23-2015 |
| 20150126461 | Skin-Permeating Peptide - The present invention relates to a skin-permeating peptide, and more particularly, the present invention relates to an isolated peptide capable of permeating the skin to deliver a drug to the skin, to an isolated polynucleotide coding the peptide, to a composition for transdermal delivery comprising the peptide, and to a peptide/cargo composite comprising the peptide and cargo. | 05-07-2015 |
| 20150133392 | Peptide Compounds to Regulate the Complement System - The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage. | 05-14-2015 |
| 20150148303 | PEPTIDES EFFECTIFE IN THE TREATMENT OF CONDITIONS REQUIRING THE REMOVAL OR DESTRUCTION OF CELLS - The embodiments are directed to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides. | 05-28-2015 |
| 20150307554 | NTS-POLYPLEX NANOPARTICLES SYSTEM FOR GENE THERAPY OF CANCER - The present invention describes a system of gene carrier nanoparticles capable of specifically internalize into cancer cells, eg, cancer cells involved in breast cancer, in vitro and in vivo. The system described allows the introduction of therapeutic genes specifically into target cells through NSTR1 receptor-mediated endocytosis of said system, making it possible to provide treatment for this type of conditions, for example by systemic, intravenous, or in situ administration. | 10-29-2015 |
| 20150361139 | CRYSTALLINE FORM OF LINACLOTIDE - Linaclotide is a guanylate cyclase type C receptor (GCC) agonist used in the treatment of gastrointestinal disorders and conditions, including irritable bowel syndrome and chronic constipation. Crystalline form II of Linaclotide is prepared in high purity and yields and shows superior chemical stability in comparison to known crystal or amorphous forms of Linaclotide. A process for the purification of Linaclotide is also provided. | 12-17-2015 |
| 20160038561 | TREATMENT OF ENDOMETRIOSIS, ANGIOGENESIS AND/OR ENDOMETRIAL LESION GROWTH - Synuclein-gamma (SNCG) inhibitors are useful for inhibiting or treating angiogenesis, endometriosis and/or endometrial lesion growth. They also potentiate efficacy of other hormonal agents in treating angiogenesis, endometriosis and/or endometrial lesion growth. | 02-11-2016 |
| 20160038602 | Compounds and Methods for Producing a Conjugate - The present disclosure provides conjugate structures and compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same. | 02-11-2016 |
| 20160061835 | IDENTIFICATION AND CHARACTERIZATION OF A PEPTIDE AFFINITY REAGENT FOR THE DETECTION OF NOROVIRUSES IN CLINICAL SAMPLES - Embodiments of the disclosure include methods and/or compositions for the detection of viral infection, including at least | 03-03-2016 |
| 20160106801 | WOUND HEALING AGENT - The present invention aims to provide a wound healing agent that inhibits bacterial growth, promotes granulation tissue formation and epithelization, and minimizes foreign body reaction in the granulation tissue. The wound healing agent of the present invention contains protein (A) and water, wherein the protein (A) contains: GAGAGS (1); and an amino acid sequence (X) and/or an amino acid sequence (X′), and the total percentage of β turns and random coils in the protein (A) as determined by circular dichroism spectroscopy is 60 to 85%, and the percentage of the total number of amino acid residues in the amino acid sequences (X) and (X′) is 50 to 70% of the total number of amino acid residues in the protein (A). Amino acid sequence (X): at least one amino acid sequence selected from the group consisting of VPGVG (2), GVGVP (3), and GAHGPAGPK (4). Amino acid sequence (X′): an amino acid sequence in which 1 or 2 amino acid residues in the amino acid sequence (X) are independently replaced by a lysine (K) or arginine (R) residue. | 04-21-2016 |
| 20160130303 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS - Novel peptide inhibitors of GSK-3, compositions containing same and uses thereof are disclosed. The novel peptide inhibitors are substrate-competitive inhibitors and have an amino acid sequence designed so as to bind to a defined binding site subunit in GSK-3. Also disclosed are GSK-3 substrate competitive inhibitors which bind to the defined binding site subunit in the enzyme. Also disclosed are mutants of GSK-3 and uses thereof for identifying a putative GSK-3 substrate competitive inhibitor. | 05-12-2016 |
| 20160168200 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | 06-16-2016 |
| 20160185820 | PROTRANSDUZIN B, A GENE TRANSFER ENHANCER - An N-terminally protected peptide having the sequence | 06-30-2016 |
| 20160200763 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | 07-14-2016 |
| 20170232058 | LINACLOTIDE STABLE COMPOSITION | 08-17-2017 |
